EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudie

Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis

Teresa Battista, Vincenzo Picone, Matteo Noto, Luca Potestio iD, Angelo Ruggiero, Fabrizio Martora iD, Matteo Megna, Lucia Genco

Expert Opinion on Drug Safety · 2024

DOI: 10.1080/14740338.2024.2392007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Opinion on Drug Safety, 2024. Verfasst von Teresa Battista und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Psoriasis, Injection Site Reaction, Severity of Illness Index, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 104 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Biological medications have significantly improved the prognosis of psoriasis patients. All biological drugs (except infliximab) for psoriasis require subcutaneous (SC) administration. Adverse events of biologic drug treatment include injection site reactions. ISRs are a local phenomenon characterized by swelling, erythema, pruritus, and pain around the injection site. AREAS COVERED: We conducted a review to analyze the differences between the ISRs of various biologics approved for psoriasis. Specifically, the review focused on anti-TNF-α, anti-IL12/23, anti-IL-17, and anti-IL-23 drugs. EXPERT OPINION: Etanercept and adalimumab have reported ISR rates of 37% and 20%, respectively, with erythema, pruritus, pain, and irritation being the most common. Citrate free (CF) solution and thinner needles have reduced ISR associated with adalimumab. Ustekinumab showed a low risk of ISR. Regarding secukinumab and ixekizumab, pain was found to be the most common ISR. The introduction of CF ixekizumab formulation has shown promise in reducing ISRs associated with ixekizumab. The risk of ISR appears insignificant with bimekizumab, brodalumab, and anti-IL23 drugs, with ISR rates ranging from less than 1% to 7.1%. The choice of biologic agent should consider ISR risk. Education on injection techniques and the use of single-dose autoinjectors/pens can mitigate ISR risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInjection Site ReactionSeverity of Illness IndexBiological ProductsHumansInjections, SubcutaneousDermatologic AgentsBiological Therapy

Stichwörter der Autor:innen

Psoriasisadverse eventsbiologic therapycutaneous adverse reactioninjection site reactions

Substanzen

Biological ProductsDermatologic Agents

Autor:innen und Institutionen

  • Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

ORCID-Profile: Luca Potestio, Fabrizio Martora

Zitieren

APA

Battista, T., Picone, V., Noto, M., Potestio, L., Ruggiero, A., Martora, F., Megna, M., & Genco, L. (2024). Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2024.2392007

Vancouver

Battista T, Picone V, Noto M, Potestio L, Ruggiero A, Martora F, et al. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert Opinion on Drug Safety. 2024. doi:10.1080/14740338.2024.2392007

BibTeX
@article{Battista2024,
  author = {Battista, Teresa and Picone, Vincenzo and Noto, Matteo and Potestio, Luca and Ruggiero, Angelo and Martora, Fabrizio and Megna, Matteo and Genco, Lucia},
  title = {Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis},
  journal = {Expert Opinion on Drug Safety},
  year = {2024},
  doi = {10.1080/14740338.2024.2392007}
}
Kostenlos starten →